MYC and breast carcinoma: Treatment with CDK1/2 inhibitors or depletion of CDK2 efficiently inhibit growth and/or induce apoptosis in triple negative/basal breast cancer, MYCN-amplified neuroblastoma and myeloid leukemia cell lines [58,134,249,250] and in mouse models of MYC-driven lymphoma and liver cancer [134,249].